Enliven Therapeutics, Inc. (ELVN) Market Cap
Enliven Therapeutics, Inc. has a market capitalization of $2.11B.
Price: $34.71
▼ -0.78 (-2.20%)
Market Cap: 2.11B
NASDAQ · time unavailable
CEO: Richard A. Fair
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2020-03-12
Website: https://www.enliventherapeutics.com
Enliven Therapeutics, Inc. (ELVN) - Company Information
Market Cap: 2.11B|Sector: Healthcare
Company Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Analyst Sentiment
From 9 Active Polls
1Y Forecast: $67.00
▲ +93.0% Potential Upside
Consensus Target Metrics
Low Bound
$59
Median
$62
High Bound
$80
Average
$67
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
📊 Historical Valuation Multiples
Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.
| Fiscal Quarter | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Period Ending | Trailing 12M | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Market Cap ($M) | 2,114 | 2,462 | 873 | 1,271 | 1,045 | 985 | 1,122 | 1,233 | 1,091 |
| Enterprise Value ($M) | 1,982 | 2,330 | 774 | 1,170 | 926 | 884 | 998 | 1,132 | 995 |
| Price to Earnings Ratio (P/E) | -22.07 | -26.05 | -7.35 | -15.77 | -10.31 | -8.63 | -12.10 | -13.31 | -13.68 |
| Price/Earnings-to-Growth Ratio (PEG) | — | — | — | — | — | — | — | — | — |
| Price to Sales Ratio (P/S) | — | — | — | — | — | — | — | — | — |
| Price to Book Ratio (P/B) | 4.81 | 5.43 | 1.90 | 2.67 | 2.14 | 3.42 | 3.62 | 4.27 | 3.58 |
| Price to Free Cash Flow Ratio (P/FCF) | -32.22 | -127.61 | -55.10 | -95.73 | -60.78 | -40.79 | -65.21 | -100.92 | -53.40 |
| Enterprise Value to Sales (EV/Sales) | — | — | — | — | — | — | — | — | — |
| Enterprise Value to EBITDA (EV/EBITDA) | -17.91 | -83.74 | -22.61 | -58.24 | -32.50 | -27.95 | -37.20 | -41.95 | -40.55 |
| Debt to Equity Ratio | 1.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
⚡ ELVN Growth Runway Model
Standard long term linear growth fadeMulti-Stage Discounted Cash Flow Sandbox
Growth runway slowdown
This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.Terminal growth rate
With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.3-Stage Financial Runway Horizon
🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)
📘 Full Research Report
AI-Generated Research: This report is for informational purposes only.
📰 Market News & Coverage
15 Stories AvailableReal-time institutional reporting and market updates for ELVN.
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains.
Enliven Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m.
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-00
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeks ELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks EHA presentation will include updated data with additional patients and longer treatment duration BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced additional, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) in an abstract accepted for an oral presentation at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden and virtually.
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029 BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduced her direct Common Stock holdings by 61.54%, from 65,000 to 25,000 shares, while indirect holdings remained at zero.
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $31.76 and last traded at $30.05, with a volume of 4931441 shares. The stock had previously closed at $27.25. Analyst Upgrades and Downgrades A number of analysts have
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month target
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast
Heron Therapeutics (NASDAQ: HRTX - Get Free Report) and Enliven Therapeutics (NASDAQ: ELVN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Insider and Institutional Ownership 80.0% of Heron
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
Enliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share. The sale represented 2.61% of the executive's holdings, reducing his trust's position from 765,188 to 745,188 shares as reported in the SEC Form 4.
Related Companies in Healthcare
AVADEL PHARMACEUTICALS ORD (AVDL)
Healthcare
$2.12B
Mkt Cap
ULTRAGENYX PHARMACEUTICAL INC (RARE)
Healthcare
$2.16B
Mkt Cap
LEMAITRE VASCULAR INC (LMAT)
Healthcare
$2.16B
Mkt Cap
ANAPTYSBIO INC (ANAB)
Healthcare
$2.17B
Mkt Cap
SELECT MEDICAL HOLDINGS CORP (SEM)
Healthcare
$2.05B
Mkt Cap
AURINIA PHARMACEUTICALS INC (AUPH)
Healthcare
$2.04B
Mkt Cap
📊 AI Financial Analysis
Powered by StockMarketInfo"Headline (2026-03-31, Q1): Revenue $0; Net income -$23.6M (EPS -$0.38). YoY (vs 2025-03-31): Net loss narrowed (from -$28.5M to -$23.6M), an improvement of ~17.2%, while EPS improved from -$0.57 to -$0.38. QoQ (vs 2025-12-31): Net loss also improved ~20.4% (from -$29.7M to -$23.6M). Margins: revenue-based margins were not meaningful as revenue was reported as $0; however, operating losses eased QoQ and YoY, consistent with some cost/interest offset improvements. Cash flow and balance sheet: Operating cash flow was -$19.3M in Q1 2026, improving vs -$15.8M in Q4 2025 (more negative QoQ), but still in line with persistent operating burn. The company ended the quarter with $132.2M cash and $320.2M short-term investments ($452.4M cash + ST investments), indicating strong liquidity. Net debt is negative (net cash position), with no meaningful debt load. Total equity was $453.4M, broadly stable/improving vs $459.6M in Q4 2025. Shareholder returns: Stock price closed at $48.11, up +199.4% over 1 year (>20% momentum), with no dividend and no disclosed buybacks in the provided cash flow. Valuation sentiment appears speculative/early-stage, supported by analyst targets around $59 (moderate upside vs $48). Revenue and Earnings-based metrics were not applicable for this analysis due to the company's pre-revenue status. The evaluation focused on cash runway, burn rate, and market sentiment instead."
Revenue Growth
Revenue was reported as $0 in all quarters provided, so no growth trajectory is observable.
Profitability
Net loss improved YoY (~17.2% less negative) and QoQ (~20.4% less negative). EPS improved from -$0.57 (2025-03-31) to -$0.38 (2026-03-31). Revenue-based margins were not meaningful due to $0 revenue.
Cash Flow Quality
Operating cash flow was -$19.3M (Q1 2026) vs -$15.8M (Q4 2025), indicating burn remains. No dividends; buybacks not evident in cash flow.
Leverage & Balance Sheet
Very low leverage: no meaningful debt; net debt is negative (net cash). Liquidity is strong with $452.4M cash + short-term investments and current ratio ~40.3x.
Shareholder Returns
Total return tailwind from strong market momentum: +199.4% 1y_change. Dividend = 0 and no repurchases shown, so appreciation is the driver.
Analyst Sentiment & Valuation
Consensus target is $59 vs $48.11 current (moderate upside). With heavy losses and pre-revenue operations, valuation likely depends on future commercialization rather than fundamentals.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Fundamentals Overview
📋 Official Regulatory 10-K / 10-Q SEC Filings
Direct authenticated documentation links to audited SEC database reports for ELVN.